Journal
LIFE-BASEL
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/life11020144
Keywords
COVID-19; SARS-CoV-2; polyclonal immunoglobulins; convalescent plasma; Cohn’ s fractionation; IgG; passive immunotherapy
Categories
Ask authors/readers for more resources
Effective treatments specific for COVID-19 are still lacking, but passive immunotherapies based on neutralizing antibodies have shown potential benefits in early disease course. COVID-19 convalescent plasma and monoclonal antibodies have been granted emergency use authorization, while hyperimmune serum derived from CCP donations or animals immunized with SARS-CoV-2 antigens may be the next nAb-derived candidate.
Effective treatments specific for COVID-19 are still lacking. In the setting of passive immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of COVID-19 convalescent plasma (CCP) anti-SARS-CoV-2 Spike protein monoclonal antibodies (mAb), which have been granted emergency use authorization, have suggested benefit in early disease course (less than 72 hours from symptoms and seronegative). Meanwhile, polyclonal immunoglobulins (i.e., hyperimmune serum), derived either from CCP donations or from animals immunized with SARS-CoV-2 antigens, are likely to become the next nAb-derived candidate. We here discuss the pros and cons of hyperimmune serum versus CCP and mAb, and summarize the ongoing clinical trials of COVID-19 hyperimmune sera.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available